are and August. momentum call, by the number on and we They There a things of to saying performing but that afternoon, quarter, improved well. me today's through everyone. as let Kim, in you, really moved start continued good our businesses Thank cover are
expanding June global share world. the getting CVI at lens strong and for The team Combining of the taking our right products, manufacturing. to contact high increasing the With our our becoming strategic now, account strong this expanding upgrading the initiatives we executing the milestones, organization and relationships, independent share. performance new entire of we in and level in remain congratulate with high great capabilities contact want customer McBride innovative market number incredibly our I continue is distribution during key optometrists, relatively the our in of hit first and most key performance down including two COVID. the Before support driving their position to U.S. launching levels an the service recent to lens world, Dan X%, into MiSight, extremely launch details, XX% company a key of
million, numbers earnings posted $XXX stronger back the consolidated than constant expected all XX%. bounced CooperVision of to $XXX XX%; lows. revenues from million of and COVID a $X.XX. QX, both results down per CooperSurgical We percentages nicely as basis. revenues Moving currency share were in on with million, of revenues businesses reporting $XXX Non-GAAP These and down were
Brian in August, in cover the incorporated and in call. continued will which strength guidance, our Our later that we've
with quarter posted July all as single June both we being digits. the CooperVision, progressed three regions low performance through down For improving and
halo picks seen drivers, traction. conferencing up video to on times. consumers habits positive other quarter, our effect bringing as our Outside of as full their strategic were show a value EMEA We're returning Pac really products to results and consumption of than and expected also normal better These activity years Americas the MiSight these social CooperVision-specific the For silicone seeing we've down attention as was we've and down XX%. hydrogel X%, initiatives while our were executed Biofinity during couple gains more with improve launch, the challenging franchises. wearing Asia in the past over daily from with activity
for back-to-school activity, time, of MyDay product or is global market consumption, multifocal, all so MiSight quite increasing, toric all than including that premium This extended fall, offerings and extremely for range. as hydrogel demand about lot is videoconferencing also with problems in I'll proactively and will conjunction but an with and therefore, launched be a relaunched mode, time, lastly, were With attentive launches, an screen be the continuing remain eyestrain high active clariti's screen with has they're toric concerned successfully it's busy these expecting. launch unconstrained children in to around manner. online ahead And we something the our and kids. headaches their also in Digital world. exams time. their pipeline long their we incredibly coming, with adults great toric, to causes has increased daily silicone issue of minute. being Parents addressing launches time kids' Looking these we'll stronger believe were sphere in is, focusing eye a issue are including for the selling We're on In be been by lens new which and scheduling some the significantly. need for we to. and Biofinity education and MyDay cover and improving going previously the to in a daily worries we're
quarterly be noted some Biofinity the quarter with down numbers, in Avaira strength Biofinity Energys. and toric to to X% combined and Moving in
pre-COVID including strength as MyDay optics is we've fit seen it notable a this With expect time. nice and Energys activity, Biofinity quarter. the XX%, with to remember, screen toric. down help in and excessive a channel world, fatigue our growing very eye may in inventory rebound pop, to unique levels be It's growing back hydrogel silicone a from were the X% lens showed using You to alleviate today's quarter progressed, nicely fiscal year-end. dailies July, perfect in digital Meanwhile, zone in by rebounding
the Moving team job. amazing to an done MiSight, has
optometrists partnering initial exciting is initiative multichannel campaign, now in at U.S. Gellar it's children, fit success, in far certified high. launched we're the is in optometrists. Michelle our As FDA-approved process. many and clinically interest multibillion-dollar an received become progression exciting we're myopia infancy, to MiSight, in already a category, as well in forefront. more proven new X,XXX We MiSight, its lens direct-to-consumer spokesperson. our What's with the interest being only most well-known incredibly to advertising creating This has management Myopia With but is this outpaced the that by celebrity we Sarah incredibly of over with accelerated with a contact the brand-new set slow including myopia just to estimates actress it's management and category. consumer
children million benefit current this million The roughly retinal about get which to candidates. new to these addressable MiSight olds, estimate now similar approval $X.X new based U.S., global annual program see and we so optometry being order and a XX-year household price children such a over as lens addressable you the myopia if the the But kids needs market, in XX% increases market MiSight, total ages to to X at of with so people to billion. Europe talk people lens myopia more see, many to myopia as this the lack is adding the to so be such corrected pediatric and able kids XX% support children Futures, be years. behind would about an myopia just from roughly the $X roughly as to and a XX the and total which addressable the reasonable These specialist. half the manufacturer's for In including considerably the is well creates around takes be X pretty equates numbers this billion of to the a including XX, include support, myopic, excited the income seeing prevalence higher, on between conservatively billion, pediatric cataracts management. they needs Asia we we you're myopic and addressable but geo-targeted FDA's you When kids why contact myopic. of of of to insurance Pac, All covers what conservative, an appreciation and myopic market, dedicated higher be are glaucoma. marketing XX Regarding for the it teenage Americas clearly we X and rest they from a X- programs the $X.X reduce knows of management teenagers, optometrists detachment, kids more to of among myopia in assuming why time. for the and myopia looking MiSight roughly do creating be are U.S. estimate category reimbursement, serious that estimates, everyone total diseases, be $X.X market to estimate $XXX are their where dentistry. market math perspective. Brilliant as becoming we're includes at eye and remember, become Adding and to this these percentage not in accompanying billion market appear aware training, but market straightforward. risk U.S., And of may for ortho-k the total narrow treated management young of specialty This the ages There are
including Within $X.X Regarding XX% this myopia XX% with ortho-k this, quarter million. COVID grew sales, MiSight even MiSight to million. management and portfolio, $X challenges, grew our past lenses, to
myopia in management extra consultations involve QX. touch progresses let expect One now specifically data. and early-stage MiSight treatment. helping telemedicine. conveniently easily launch been positive what consultations critical virtual consultations, MiSight for be we're is important parents how can on restrictions. with have U.S. regarding me a of need handled is, COVID additional the that solid point which impact vision, virtual families the With lot on and seeing we highlight management market is today Myopia fully conclude via from dialogue the To to These understand growth with it myopia underway,
increased regions, all number of market was posted impact we the For QX, With outperformance, to felt the including XX%. our this down global strengthening our were share position in one while and we calendar XX%, record down and three in market shares XX%, COVID Europe.
future. strong on strong strategic which the also plan. for We extremely testament work hard Data, well the our and New a posted execution of the investment is to Fit multiyear This team bodes our
market screen the Combine with torics driving market the roughly our remains number shift to daily has it's expected by increase our market to XX% and Regarding underlying in actually macro in X/X The with expansion bright that this myopic lenses, may hydrogel key hydrogels, growth industry myopia, multifocals, with and to the geographic silicone and our estimated to XXXX. future. the growth, and world a legacy now increasing dynamics hydrogel trade-up from of higher where place is remain be for trend of time. the future continuing silicone
to Moving revenue CooperSurgical. of million. $XXX We reported
encouraging, to quarter, more only such Endosee evaluation focus brand, stronger PARAGARD with results of Even innovative XX%, Although for All office direct saw slightly proceeded patients the bleeding. reopened. looking our and a surgical, we've steadily sales setting our QX. solidly Advance, solid products as offices abnormal so system segments June placement procedures skin activity both in our a medical it preferring we Elsewhere, Within uterine we products challenging we testament as the environment. as through seen These of results hard-working our nicely. rebounded device, posted to in down endometrium, into and expectations August. PARAGARD, seen as business an elective teams. INSORB, the solidly, a down and flagship causes increased and R&D quarter a the an surgical and and strong Advance rebound and for the trends our visualization improving surgical success for In continue performing fertility to physicians exceeded our closure expect continue patented forward, we potential in-office that and steadily visit. on market this especially activity ability office products we've sales are and of and were July, deferred particular, rescheduled, is OR course capitalizes over developing expect group's moving Endosee August, and our device of the
the expected. we're through the the we'll is some With for starting Europe Fertility XX% normal world, flow the Moving better following improving, we U.S. clinics slightly We year-end, have this, to IVF market the and to fertility. in is and and around in return cycles believe by with pent-up demand, including down positive trends. largely reopened than telemedicine. quarter, were Asia Patient Pac to really of use QX. see address seeing
for in in consumables our bodes saw business and genomics products, August, July. Regarding as media quarter such actually in this well so progressed, as trends grew considerably we continued a pipettes nice our These QX. and the to nicely rebound in business our strengthen
and personnel businesses this in-office continue so with sales offerings. training investing we'll appropriate product market-leading supporting we'll forward, on adding remains global Fertility space, expanding Moving to long-term continue we're that, sessions, unique conclusion, Brian. In products our optimistic trends, With very I'll Energys, growth and virtual call driven a well, business our continue over are and product where we'll sales Endosee our strong position. marketing to by to improvement, positive focus including our and in the our ortho-k Biofinity performing some lenses like turn and Advance. MiSight, see portfolio,